Out-licensing

Our European client has a Class I medical device (CE marked) for the targeted transdermal administration of liquid substances.

Facilitates the penetration of substances with a unique skin preparation prior to application of an empty patch that serves to retain the liquid formulations.

The clinically tested delivery technology enables targeted delivery of substances to the following tissues: (1) Lymphoid tissues - e.g. antigens, nanomedicines; (2) Blood - e.g. small molecules; (3) Dermis, epidermis - e.g. cosmetics

Facilitates the penetration of substances with a unique skin preparation prior to application of an empty patch that serves to retain the liquid formulations.

As the patch does not contain any of the ingredients, there is no concentration or dose limit of the substance; dose can be adjusted by volume, concentration, patch size, or number of patches and the product can be stored separately from the patch. This feature of the device also allows an effective but fast transdermal administration of products that have limited stability at room temperature.

 

Early Stage

Our clients are seeking European partners interested in in-licensing this technology, who can use the transdermal for delivery of their own liquid, frozen or lyophilized formulations.